Literature DB >> 11274701

Quantifiable dose-dependent withdrawal after morphine discontinuation in a rat model.

L Langerman1, B Piscoun, M Bansinath, Y Shemesh, H Turndorf, G J Grant.   

Abstract

We evaluated the intensity of the withdrawal symptoms after the discontinuation of the morphine infusion in rats. Opiate addiction was induced by progressively increasing intraperitoneal morphine infusion rates. The control group (Group 1) received normal saline. The initial morphine rates were 1, 4, and 16 mg kg(-1) h for Groups 2, 3, and 4, respectively. Infusion rates were gradually increased by a factor of 1.4, 2, 2.8, and 4 on the second, third, fourth, and fifth days, respectively. The last rate was used for 48 h and then infusions were disconnected. Weight reduction, food consumption, and water intake were used for evaluation of withdrawal. All morphine groups showed a significant reduction of body weight during the 4 postdiscontinuation days and a decline in food and water intake on the first postdiscontinuation day. All changes were dependent on the morphine infusion concentration. No changes were observed in the control group. We suggest that the rat model used in this study may be utilized for quantification of spontaneous withdrawal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274701     DOI: 10.1016/s0091-3057(00)00442-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  Elevation of BDNF exon I-specific transcripts in the frontal cortex and midbrain of rat during spontaneous morphine withdrawal is accompanied by enhanced pCreb1 occupancy at the corresponding promoter.

Authors:  Danil I Peregud; Leonid F Panchenko; Natalia V Gulyaeva
Journal:  Neurochem Res       Date:  2014-11-13       Impact factor: 3.996

2.  Rapid neuroadaptation in the nucleus accumbens and bed nucleus of the stria terminalis mediates suppression of operant responding during withdrawal from acute opioid dependence.

Authors:  S H Criner; J Liu; G Schulteis
Journal:  Neuroscience       Date:  2006-12-11       Impact factor: 3.590

3.  Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in Fischer rats: possible role of mu-opioid receptors.

Authors:  Katharine M Seip-Cammack; Brian Reed; Yong Zhang; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2012-07-25       Impact factor: 4.530

4.  Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats.

Authors:  Ziva D Cooper; Yong-Gong Shi; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2010-08-05       Impact factor: 4.530

5.  Measuring the incentive value of escalating doses of heroin in heroin-dependent Fischer rats during acute spontaneous withdrawal.

Authors:  Katharine M Seip; Brian Reed; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2011-07-07       Impact factor: 4.530

6.  Affective and neuroendocrine effects of withdrawal from chronic, long-acting opiate administration.

Authors:  Kathryn L Hamilton; Andrew C Harris; Jonathan C Gewirtz
Journal:  Brain Res       Date:  2013-09-26       Impact factor: 3.252

7.  Effects of repeated exposure to morphine in adolescent and adult male C57BL/6J mice: age-dependent differences in locomotor stimulation, sensitization, and body weight loss.

Authors:  Wouter Koek
Journal:  Psychopharmacology (Berl)       Date:  2013-10-06       Impact factor: 4.530

8.  Proopiomelanocortin (POMC) expression and conditioned place aversion during protracted withdrawal from chronic intermittent escalating-dose heroin in POMC-EGFP promoter transgenic mice.

Authors:  K Niikura; Y Zhou; A Ho; M J Kreek
Journal:  Neuroscience       Date:  2013-01-18       Impact factor: 3.590

9.  Morphine deprivation increases self-administration of the fast- and short-acting mu-opioid receptor agonist remifentanil in the rat.

Authors:  Ziva D Cooper; Yen Nhu-Thi Truong; Yong-Gong Shi; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2008-05-30       Impact factor: 4.030

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.